Commentary|Videos|July 10, 2024

Leveraging eCOA Technologies to Create Greater Patient Centricity

In part 3 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime touches on the importance of utilizing patient-reported outcomes.

ACT: How can sponsors leverage electronic clinical outcome assessment (eCOA) technologies to facilitate the collection and management of patient-reported outcomes (PROs)? How does this contribute to a more patient-centric approach?

Birchard: I am actually such a big fan of ePROs. I've been working in the clinical trial industry for eight, nine years now, because after graduate school, I was focusing on patient-centric research design, and I really wanted to find a space where that was happening, and in the clinical trial space, especially in the ePRO space, was where I saw the most influential work being done—incorporating patient and caregiver knowledge as a crucial part of science and understanding knowledge as both live knowledge and scientific knowledge. It was really exciting for me to get into this space. I always say I'm a patient first. That's why I got into this industry.

Patient-reported outcomes allow patients to report symptoms at home, they allow patients a lot more convenience and flexibility of how they report symptoms. Also, the biggest part for me is that they actually often, if done right, and in a patient centric way give patients a voice that they're not always granted in in our system. I really strongly believe that ePROs specifically have so much value in the clinical trial industry because, again, they give patients more opportunities to use these tools as a voice and a way to report how we're living with or managing our illnesses. I think that, in itself, is crucial to the conversation of patient centricity and building these tools with patients is also very important.


Related to this article

What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.